Abstract
Cannabis use has attracted much attention as a potential therapeutic target for cancer, cancer-related disorders, and neurological diseases. Cannabinoids play a role in various physiological processes, including appetite stimulation, energy homeostasis, pain modulation, and chemotherapy-induced nausea and vomiting control. However, because pharmacokinetic and pharmacodynamic interactions can be experienced in drug combinations, we endeavored to describe the various pharmacokinetic and pharmacodynamic interactions, as well as potential therapeutic cannabis drug interactions and the cannabis safety profile. Evidence on cannabinoids’ adverse drug responses and drug-drug interactions with other prescription drugs has been delivered. Although cannabis is usually well-tolerated, bidirectional actions by metabolizing enzymes with concurrently administered drugs cannot be ruled out. To ensure their wellness, caution should be exercised in thoroughly scrutinizing the responses of cannabis users to various medications. This is remarkably true for aging individuals who have multiple medical conditions. Once a balanced approach is developed, the legal use of Cannabis might be productive and valuable for therapeutic applications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AUC:
-
Area under the curve
- CBD:
-
Cannabidiol
- CNS:
-
Central nervous system
- ECS:
-
Endocannabinoid system
- FDA:
-
Food and drug administration
- NIDA:
-
National Institute on drug abuse
- PNS:
-
Peripheral nervous system
- THC:
-
Tetrahydrocannabinol
- USA:
-
United States of America
References
Abouchedid R, Ho JH, Hudson S et al (2016) Acute toxicity associated with use of 5f-derivations of synthetic cannabinoid receptor agonists with analytical confirmation. J Med Toxicol 12(4):396–401. https://doi.org/10.1007/s13181-016-0571-7
Alipour A, Patel PB, Shabbir Z, Gabrielson S (2019) Review of the many faces of synthetic cannabinoid toxicities. Ment Health Clin 9(2):93–99. https://doi.org/10.9740/mhc.2019.03.093
Badowski ME, Yanful PK (2018) Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. Ther Clin Risk Manag 14:643–651. https://doi.org/10.2147/tcrm.S126849
Benbadis SR, Sanchez-Ramos J, Bozorg A et al (2014) Medical marijuana in neurology. Expert Rev Neurother 14(12):1453–1465. https://doi.org/10.1586/14737175.2014.985209
Bowman M, Pihl RO (1973) Cannabis: psychological effects of chronic heavy use. Psychopharmacologia 29(2):159–170. https://doi.org/10.1007/BF00422648
Bray JW, Zarkin GA, Ringwalt C, Qi J (2000) The relationship between marijuana initiation and dropping out of high school. Health Econ 9(1):9–18. https://doi.org/10.1002/(sici)1099-1050(200001)9:1<9::aid-hec471>3.0.co;2-z
Burstein S, Rosenfeld J, Wittstruck T (1972) Isolation and characterization of two major urinary metabolites of 1 -tetrahydrocannabinol. Science 176(4033):422–423. https://doi.org/10.1126/science.176.4033.422
Carley DW, Prasad B, Reid KJ et al (2018) Pharmacotherapy of apnea by cannabimimetic enhancement, the PACE clinical trial: effects of dronabinol in obstructive sleep apnea. Sleep 41(1):184. https://doi.org/10.1093/sleep/zsx184
Caspi A, Moffitt TE, Cannon M et al (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57(10):1117–1127. https://doi.org/10.1016/j.biopsych.2005.01.026
Cavazos-Rehg PA, Krauss MJ, Cahn E et al (2019) Marijuana promotion online: an investigation of dispensary practices. Prev Sci 20(2):280–290. https://doi.org/10.1007/s11121-018-0889-2
Center for Behavioral Health Statistics and Quality (2016) Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16–4984, NSDUH Series H-51). http://www.samhsa.gov/data/. Accessed 28 Sept 2021.
Chiang CN, Rapaka RS (1987) Pharmacokinetics and disposition of cannabinoids. NIDA Res Monogr 79:173–188
Costiniuk CT, Saneei Z, Routy JP et al (2019) Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation. BMJ Open 9(1):e024793. https://doi.org/10.1136/bmjopen-2018-024793
Cox EJ, Maharao N, Patilea-Vrana G et al (2019) A marijuana-drug interaction primer: precipitants, pharmacology, and pharmacokinetics. Pharmacol Ther 201:25–38. https://doi.org/10.1016/j.pharmthera.2019.05.001
Crane NA, Schuster RM, Fusar-Poli P, Gonzalez R (2013) Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev 23(2):117–137. https://doi.org/10.1007/s11065-012-9222-1
D'Souza DC, Perry E, MacDougall L et al (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29(8):1558–1572. https://doi.org/10.1038/sj.npp.1300496
Dewey WL, McMillan DE, Harris LS, Turk RF (1973) Distribution of radioactivity in brain of tolerant and nontolerant pigeons treated with 3 H- 9 -tetrahydrocannabinol. Biochem Pharmacol 22(3):399–405. https://doi.org/10.1016/0006-2952(73)90420-6
Di Forti M, Iyegbe C, Sallis H et al (2012) Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 72(10):811–816. https://doi.org/10.1016/j.biopsych.2012.06.020
Dinieri JA, Hurd YL (2012) Rat models of prenatal and adolescent cannabis exposure. Methods Mol Biol 829:231–242. https://doi.org/10.1007/978-1-61779-458-2_14
Gable RS (1993) Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically. Am J Drug Alcohol Abuse 19(3):263–281. https://doi.org/10.3109/00952999309001618
Gogtay N, Giedd JN, Lusk L et al (2004) Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A 101(21):8174–8179. https://doi.org/10.1073/pnas.0402680101
Gonçalves J, Rosado T, Soares S et al (2019) Cannabis and its secondary metabolites: their use as therapeutic drugs, toxicological aspects, and analytical determination. Medicine 6(1):31. https://doi.org/10.3390/medicines6010031
Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42(4):327–360. https://doi.org/10.2165/00003088-200342040-00003
Grotenhermen F (2007) The toxicology of cannabis and cannabis prohibition. Chem Biodivers 4(8):1744–1769. https://doi.org/10.1002/cbdv.200790151
Grotenhermen F, HäuBermann K (2017) Cannabis: prescription help for doctors, 1st edn, (German). Scientific Publishing Company, Stuttgart, Germany
Hall W, Degenhardt L (2009) Adverse health effects of non-medical cannabis use. Lancet 374(9698):1383–1391. https://doi.org/10.1016/s0140-6736(09)61037-0
Holland J (ed) (2010) The pot book: a complete guide to Cannabis. Park Street Press, Rochester, USA
Huestis MA (2007) Human cannabinoid pharmacokinetics. Chem Biodivers 4(8):1770–1804. https://doi.org/10.1002/cbdv.200790152
Huestis MA, Henningfield JE, Cone EJ (1992) Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16(5):276–282. https://doi.org/10.1093/jat/16.5.276
Hunt CA, Jones RT (1980) Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 215(1):35–44
Jameson JL, Fauci AS, Kasper DL et al (2018) Harrison’s primciples of internal medicine, 20th edn. McGraw-Hill Education, USA
Johnston LD, O’Malley PM, Miech RA et al (2016) Monitoring the future national survey results on drug use, 1975–2015: overview, key findings on adolescent drug use. Ann Arbor, Institute for Social Research, The University of Michigan, USA
Kahan M, Srivastava A (2014) New medical marijuana regulations: the coming storm. CMAJ 186(12):895–896. https://doi.org/10.1503/cmaj.131821
Kelly BF, Nappe TM (2021) Cannabinoid toxicity. In: StatPearls. StatPearls Publishing, Treasure Island
Lachenmeier DW, Rehm J (2015) Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Sci Rep 5:8126–8126. https://doi.org/10.1038/srep08126
Law B, Mason PA, Moffat AC, Gleadle RI, King LJ (1984) Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol 36(5):289–294. https://doi.org/10.1111/j.2042-7158.1984.tb04376.x
Lee CC, Chiang CN (1985) Maternal-fetal transfer of abused substances: pharmacokinetic and pharmacodynamic data. NIDA Res Monogr 60:110–147
Lemberger L, Silberstein SD, Axelrod J, Kopin IJ (1970) Marihuana: studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. Science 170(3964):1320–1322. https://doi.org/10.1126/science.170.3964.1320
Lucas CJ, Galettis P, Schneider J (2018) The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 84(11):2477–2482. https://doi.org/10.1111/bcp.13710
McCain KR, Jones JO, Chilbert KT et al (2018) Impaired driving associated with the synthetic cannabinoid 5f-Adb. J Forensic Sci Criminol 6(1):105. https://doi.org/10.15744/2348-9804.6.105
Mechoulam R, BenZvi Z, Agurell S et al (1973) Delta 6-tetrahydrocannabinol-7-oic acid, a urinary delta 6-THC metabolite: isolation and synthesis. Experientia 29(10):1193–1195. https://doi.org/10.1007/bf01935065
Mechoulam R, Gaoni Y (1965) A total synthesis of dl-delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 20(87):3273–3275. https://doi.org/10.1021/ja01092a065
Medicinenet (2021) Medical definition of contraindication. https://www.medicinenet.com/contraindication/definition.htm. Accessed 28 Sept 2021
Meier MH, Caspi A, Ambler A et al (2012a) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 109(40):E2657–E2664. https://doi.org/10.1073/pnas.1206820109
Meier MH, Caspi A, Ambler A et al (2012b) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci 109(40):E2657–E2664. https://doi.org/10.1073/pnas.1206820109
Millar SA, Stone NL, Yates AS, O'Sullivan SE (2018) A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol 9:1365. https://doi.org/10.3389/fphar.2018.01365
Munjal M, ElSohly MA, Repka MA (2006) Chemical stabilization of a Delta9-tetrahydrocannabinol prodrug in polymeric matrix systems produced by a hot-melt method: role of microenvironment pH. AAPS PharmSciTech 7(3):71–71. https://doi.org/10.1208/pt070371
Musto DF (1972) The marihuana tax act of 1937. Arch Gen Psychiatry 26(2):101–108. https://doi.org/10.1001/archpsyc.1972.01750200005002
NIDA (2019) National institute on drug abuse. Marijuana DrugFacts. https://www.drugabuse.gov/publications/drugfacts/marijuana. Accessed 10 June 2021
Ohlsson A, Lindgren JE, Wahlen A et al (1980) Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28(3):409–416. https://doi.org/10.1038/clpt.1980.181
Parakh P (2010) Adverse health effects of non-medical cannabis use. Lancet 375(9710):196–197; author reply 197. https://doi.org/10.1016/s0140-6736(10)60087-6
Patton GC, Coffey C, Carlin JB et al (2002) Cannabis use and mental health in young people: cohort study. BMJ 325(7374):1195–1198. https://doi.org/10.1136/bmj.325.7374.1195
Pertwee RG (2014) Handbook of Cannabis. Oxford University Press, UK
Pisanti S, Bifulco M (2019) Medical Cannabis: a plurimillennial history of an evergreen. J Cell Physiol 234(6):8342–8351. https://doi.org/10.1002/jcp.27725
Radhakrishnan R, Wilkinson ST, D'Souza DC (2014) Gone to pot - a review of the association between Cannabis and psychosis. Front Psychiatry 5:54–54. https://doi.org/10.3389/fpsyt.2014.00054
Ramesh D, Haney M, Cooper ZD (2013) Marijuana's dose-dependent effects in daily marijuana smokers. Exp Clin Psychopharmacol 21(4):287–293. https://doi.org/10.1037/a0033661
Repp KK, Raich AL (2014) Marijuana and health: a comprehensive review of 20 years of research. Department of Health and Human Services, Washington County Government, USA
Rosenkrantz H, Heyman IA, Braude MC (1974) Inhalation, parenteral and oral LD50 values of delta 9-tetrahydrocannabinol in Fischer rats. Toxicol Appl Pharmacol 28(1):18–27. https://doi.org/10.1016/0041-008x(74)90126-4
Russo EB (2005) Cannabis in India: ancient lore and modern medicine. In: Mechoulam R (ed) Cannabinoids as therapeutics, 1st edn. Birkhäuser, Cham, pp 1–23
Russo E, Guy GW (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66(2):234–246. https://doi.org/10.1016/j.mehy.2005.08.026
Sachs J, McGlade E, Yurgelun-Todd D (2015) Safety and toxicology of cannabinoids. Neurotherapeutics 12(4):735–746. https://doi.org/10.1007/s13311-015-0380-8
Schatman ME (2015) Medical marijuana: the state of the science. https://www.medscape.com/viewarticle/839155. Accessed 2015
Scurlock JA, Andersen BR (2005) In: Scurlock JA, Andersen BR (eds) Diagnoses in Assyrian and Babylonian medicine [electronic resource]: ancient sources, translations, and modern medical analyses. University of Illinois Press, Urbana
Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287(9):1123–1131. https://doi.org/10.1001/jama.287.9.1123
Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR (2004) Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannabinol. J Pharm Pharmacol 56(3):291–297. https://doi.org/10.1211/0022357022791
Tobe M, Naito K, Kurokawa Y (1989) Chronic toxicity study on formaldehyde administered orally to rats. Toxicology 56(1):79–86. https://doi.org/10.1016/0300-483x(89)90213-8
Tormey W (2010) Adverse health effects of non-medical cannabis use. Lancet 375(9710):196; author reply 197. https://doi.org/10.1016/s0140-6736(10)60086-4
Volkow ND, Baler RD, Compton WM, Weiss SR (2014) Adverse health effects of marijuana use. N Engl J Med 370(23):2219–2227. https://doi.org/10.1056/NEJMra1402309
Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M (1983) Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 34(3):352–363. https://doi.org/10.1038/clpt.1983.179
Watanabe K, Tanaka T, Yamamoto I, Yoshimura H (1988) Brain microsomal oxidation of delta 8- and delta 9-tetrahydrocannabinol. Biochem Biophys Res Commun 157(1):75–80. https://doi.org/10.1016/s0006-291x(88)80013-5
Williams PL, Moffat AC (1980) Identification in human urine of delta 9-tetrahydrocannabinol-11-oic acid glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol 32(7):445–448. https://doi.org/10.1111/j.2042-7158.1980.tb12966.x
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Ramesh, S. et al. (2022). Understanding the Pharmacokinetics, Safety Profile, and Scope of the Concerned Issue to Evade the Consumption of Cannabis/Marijuana. In: Agrawal, D.C., Kumar, R., Dhanasekaran, M. (eds) Cannabis/Marijuana for Healthcare. Springer, Singapore. https://doi.org/10.1007/978-981-16-8822-5_8
Download citation
DOI: https://doi.org/10.1007/978-981-16-8822-5_8
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-8821-8
Online ISBN: 978-981-16-8822-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)